Format

Send to

Choose Destination
Geroscience. 2019 Apr;41(2):101-108. doi: 10.1007/s11357-019-00057-3. Epub 2019 Feb 12.

Taming expectations of metformin as a treatment to extend healthspan.

Author information

1
Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
2
Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
3
Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. Benjamin-miller@omrf.org.

Abstract

The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow aging in humans. While the Targeting Aging with Metformin (TAME) proposal and other small-scale clinical trials have the potential to support aging as a treatment indication, we propose that the goals of the TAME trial might not be entirely consistent with the Geroscience goal of extending healthspan. There is expanding epidemiological support for the health benefits of metformin in individuals already diagnosed with overt chronic disease. However, it remains to be understood if these protective effects extend to those free of chronic disease. Within this editorial, we seek to highlight critical gaps in knowledge that should be considered when testing metformin as a treatment to target aging.

KEYWORDS:

Aging; Healthspan; Metformin; Slowed aging

PMID:
30746605
DOI:
10.1007/s11357-019-00057-3

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center